Prosecution Insights
Last updated: May 29, 2026
Application No. 17/725,689

AMIDE-LINKED CONJUGATE COMPOUNDS AND USES THEREOF

Non-Final OA §102
Filed
Apr 21, 2022
Priority
Jun 12, 2015 — provisional 62/175,118 +3 more
Examiner
COLEMAN, BRENDA LIBBY
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Simon Fraser University
OA Round
4 (Non-Final)
75%
Grant Probability
Favorable
4-5
OA Rounds
0m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
1208 granted / 1617 resolved
+14.7% vs TC avg
Strong +16% interview lift
Without
With
+15.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
34 currently pending
Career history
1656
Total Applications
across all art units

Statute-Specific Performance

§101
2.8%
-37.2% vs TC avg
§103
9.5%
-30.5% vs TC avg
§102
12.3%
-27.7% vs TC avg
§112
49.8%
+9.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1617 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-13, 15, 17, 19-21, 25, 26 and 30-34 are pending in the application. This action is in response to applicants' amendment dated April 23, 2026. Claims 1, 6, 7, 21, 25, 26 and 30-34 have been amended and claims 14, 16 and 18 have been canceled. Response to Amendment Applicant's arguments filed April 23, 2026 have been fully considered with the following effect: The applicants’ amendments are sufficient to overcome the 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph rejection, labeled paragraph 3) in the last office action, which is hereby withdrawn. The applicant's amendments and arguments are sufficient to overcome the 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph rejections, labeled paragraph 4a) and b) in the last office action, which are hereby withdrawn. The applicant's amendments and arguments are sufficient to overcome the 35 U.S.C. 102(a)(1), anticipation rejection, labeled paragraph 5) in the last office action, which is hereby withdrawn. In view of the amendment dated April 23, 2026, the following new grounds of rejection apply: Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 7 and 21 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 2055490-48-5 where n is 2. Allowable Subject Matter Claims 1-6, 8-13, 15, 17, 19, 20, 25, 26 and 30-34 are allowed. None of the prior art of record teaches the compounds, compositions and method of use of the compounds as claimed herein. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRENDA L COLEMAN whose telephone number is (571)272-0665. The examiner can normally be reached Mon-Fri 10-6 (flex). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey H. Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRENDA L COLEMAN/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Show 2 earlier events
May 30, 2025
Response Filed
Jun 17, 2025
Final Rejection mailed — §102
Aug 01, 2025
Response after Non-Final Action
Sep 17, 2025
Request for Continued Examination
Oct 02, 2025
Response after Non-Final Action
Oct 23, 2025
Non-Final Rejection mailed — §102
Apr 23, 2026
Response Filed
May 14, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12637463
TRICYCLIC KINASE INHIBITORS AND USES THEREOF
4y 1m to grant Granted May 26, 2026
Patent 12637429
NOVEL OXIDIZED LAPPACONITINE DERIVATIVE AND USE THEREOF
3y 8m to grant Granted May 26, 2026
Patent 12636310
THERAPEUTIC AGENT FOR SHORT TEAR BREAKUP TIME-TYPE DRY EYE AND EYE DROPS CONTAINING SAME
3y 0m to grant Granted May 26, 2026
Patent 12630565
DNA-DEPENDENT PROTEIN KINASE INHIBITOR
4y 5m to grant Granted May 19, 2026
Patent 12629359
STRUCTURAL ANALOGUES OF METHYLPHENIDATE AS PARKINSON'S DISEASE-MODIFYING AGENTS
3y 3m to grant Granted May 19, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
75%
Grant Probability
90%
With Interview (+15.7%)
2y 4m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1617 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month